Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | TTR | P02766 | 2/20 | 0.40 |
| ▸ | ALB | P02768 | 2/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | GRM5 | P41594 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21121844 | 0.84 | TTR (0.48) | MEN1KMT2ATTRALBHTT | |
| SCHEMBL1179216 | 0.84 | KDM4E (0.45) | MEN1KMT2ATTRALBKDM4E | |
| SCHEMBL16976904 | 0.76 | KDM4E (0.39) | MEN1KMT2ATTRALBKDM4E | |
| SCHEMBL17069067 | 0.75 | GRM5 (0.49) | MEN1KMT2AHTTKDM4EGRM5 | |
| SCHEMBL24156951 | 0.75 | TTR (0.34) | MEN1KMT2ATTRALBHTT | |
| SCHEMBL583616 | 0.74 | GRM5 (0.48) | MEN1KMT2AKDM4EGRM5LMNA | |
| SCHEMBL955626 | 0.74 | NOS3 (0.52) | HTTKDM4EGRM5 | |
| SCHEMBL23860799 | 0.74 | HTT (0.42) | MEN1KMT2ATTRALBHTT | |
| SCHEMBL27919228 | 0.74 | TTR (0.45) | MEN1KMT2ATTRALBKDM4E | |
| SCHEMBL24156964 | 0.74 | MEN1 (0.36) | MEN1KMT2ATTRALBHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080161365-A1 | e.g. 4-{3-fluoro-3-[2-methyl-6-(3-trifluoromethyl-benzylcarbamoyl)-pyridin-4-yl]-propyl}-benzoic acid; collagenases inhibitor; osteoarthritis or rheumatoid arthritis, heart failure, breast cancer metastasis, and other diseases that are mediated by MMP-13 overactivity | PFIZER INC. (US) | 2008-07-03 | — | — | US | disclosed |
| EP-1828133-A2 | METHYLENE INHIBITORS OF MATRIX METALLOPROTEINASE | Warner-Lambert Company LLC (US) | 2007-09-05 | — | — | EP | disclosed |
| WO-2006061715-A2 | METHYLENE INHIBITORS OF MATRIX METALLOPROTEINASE | WARNER-LAMBERT COMPANY LLC (US) | 2006-06-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080161365-A1 | e.g. 4-{3-fluoro-3-[2-methyl-6-(3-trifluoromethyl-benzylcarbamoyl)-pyridin-4-yl]-propyl}-benzoic acid; collagenases inhibitor; osteoarthritis or rheumatoid arthritis, heart failure, breast cancer metastasis, and other diseases that are mediated by MMP-13 overactivity | MMP13, MMP9, MMP11 | MEN1 3461/4885KMT2A 792/4885TTR 1058/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.